These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 29764404)

  • 1. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
    Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
    BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
    Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
    Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma.
    Pan CC; Chung MY; Ng KF; Liu CY; Wang JS; Chai CY; Huang SH; Chen PC; Ho DM
    J Pathol; 2008 Feb; 214(3):387-93. PubMed ID: 18085521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.
    El-Hashemite N; Zhang H; Henske EP; Kwiatkowski DJ
    Lancet; 2003 Apr; 361(9366):1348-9. PubMed ID: 12711473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
    Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
    Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms.
    Kenerson H; Folpe AL; Takayama TK; Yeung RS
    Hum Pathol; 2007 Sep; 38(9):1361-71. PubMed ID: 17521703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.
    Giannikou K; Malinowska IA; Pugh TJ; Yan R; Tseng YY; Oh C; Kim J; Tyburczy ME; Chekaluk Y; Liu Y; Alesi N; Finlay GA; Wu CL; Signoretti S; Meyerson M; Getz G; Boehm JS; Henske EP; Kwiatkowski DJ
    PLoS Genet; 2016 Aug; 12(8):e1006242. PubMed ID: 27494029
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
    Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
    Brakemeier S; Bachmann F; Budde K
    Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biallelic
    Maroto P; Anguera G; Roldan-Romero JM; Apellániz-Ruiz M; Algaba F; Boonman J; Nellist M; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C
    J Natl Compr Canc Netw; 2018 Apr; 16(4):352-358. PubMed ID: 29632054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of the mTOR pathway in hepatic angiomyolipoma with emphasis on the epithelioid variant and loss of heterogeneity of TSC1/TSC2.
    Huang SC; Chuang HC; Chen TD; Chi CL; Ng KF; Yeh TS; Chen TC
    Histopathology; 2015 Apr; 66(5):695-705. PubMed ID: 25234729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelioid angiomyolipoma of the liver in a patient with Li-Fraumeni syndrome: a case report.
    Yang Y; Lee J; Woo CG; Lee OJ; Son SM
    Diagn Pathol; 2024 Jan; 19(1):16. PubMed ID: 38243242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal disease in adults with TSC2/PKD1 contiguous gene syndrome.
    Martignoni G; Bonetti F; Pea M; Tardanico R; Brunelli M; Eble JN
    Am J Surg Pathol; 2002 Feb; 26(2):198-205. PubMed ID: 11812941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
    Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
    Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dia-gnostic Challenges and Extraordinary Treatment Response in Rare Malignant PEComa Tumor of the Kidney.
    Huľová S; Sycova-Mila Z; Macák D; Janega P; Chovanec M; Mardiak J; Mego M
    Klin Onkol; 2018; 31(6):448-452. PubMed ID: 30545225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexistence of renal epithelioid angiomyolipoma and clear cell carcinoma in patients without tuberous sclerosis.
    Cao QH; Liu F; Xiao P; Tian XY; Li B; Li Z
    Int J Surg Pathol; 2012 Apr; 20(2):196-200. PubMed ID: 21742645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal epithelioid angiomyolipoma with malignant features: Histological evaluation and novel immunohistochemical findings.
    Konosu-Fukaya S; Nakamura Y; Fujishima F; Kasajima A; McNamara KM; Takahashi Y; Joh K; Saito H; Ioritani N; Ikeda Y; Arai Y; Watanabe M; Sasano H
    Pathol Int; 2014 Mar; 64(3):133-41. PubMed ID: 24698423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
    Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
    J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal angiomyolipoma (AML) harboring a missense mutation of
    Idogawa M; Hida T; Tanaka T; Ohira N; Tange S; Sasaki Y; Uhara H; Masumori N; Tokino T; Natori H
    Cancer Biol Ther; 2020 Apr; 21(4):315-319. PubMed ID: 31847710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.